Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Lucemyra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indoco Remedies Gets USFDA Nod to Market Lofexidine Tablets with 180 Days Exclusivity
Details : Lofexidine is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Product Name : Lucemyra-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2024
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2023
Lead Product(s) : Lofexidine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Lofexidine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : US WorldMeds
Deal Size : Undisclosed
Deal Type : Partnership
US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic
Details : US WorldMeds, in conjunction with FEMA and their partnership with Healthcare Ready, is making a donation of LUCEMYRA valued at approximately $100,000 to NorthLakes Community Clinic, a federally qualified health center located in northern Wisconsin.
Product Name : Lucemyra
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2020
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : US WorldMeds
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : US Department of Defense | RTI International | Michael E. DeBakey VA Medical Center | US WorldMeds | Foundation for Advancing Veterans' Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2020
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : US Department of Defense | RTI International | Michael E. DeBakey VA Medical Center | US WorldMeds | Foundation for Advancing Veterans' Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2019
Lead Product(s) : Lofexidine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : US WorldMeds
Deal Size : Inapplicable
Deal Type : Inapplicable
Lofexidine for Adults Undergoing Lumbar Spine Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2019
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : US WorldMeds
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2019
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable